Approval · Notice of Compliance 17908 · 2016
ENTYVIO: Notice of Compliance 17908
Issued March 22, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17908
- Date
- March 22, 2016
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: for the tereatment of adult patients with moderately to severely active crohn's disease who have had an inadequate respone with, lost response to or were intolerant to a tumor necrosis factor-alpha (tnfa) antagonist or immunomodulators, or had inadequate response, intolerance or demonstrated dependace on corticosteroids
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ENTYVIO | Not yet assigned | — |
Medicinal ingredients
- VEDOLIZUMAB 300 MG per VIAL